Claims for Patent: 12,357,711

Summary for Patent: 12,357,711

Title:	PSMA binding dual mode radiotracer and therapeutic
Abstract:	The present invention relates to a compound according to formula (V): or a pharmaceutically acceptable salt thereof, optionally containing a chelated radioactive cation and wherein F is optionally 18F.
Inventor(s):	Alexander Josef Wurzer, Hans-Jürgen Wester, Matthias Johannes Eiber
Assignee:	Technische Universitaet Muenchen Klinikum Rechts Der Isar , Technische Universitaet Muenchen , Klinikum Rechts der Isar der Technischen Universitaet Muenchen
Application Number:	US17/426,962
Patent Claims:	1. The compound according to formula (V): or a pharmaceutically acceptable salt thereof, wherein F is optionally 18F. 2. The compound according to f claim 1, comprising a chelated cation selected from the cations of Sc, Cu, Ga, Y, In, Tb, Ho, Lu, Re, Pb, Bi, Ac, Er and Th. 3. The compound according to claim 2, wherein the chelated cation is Ga. 4. A method of producing the compound according to claim 1, comprising the steps of: a) reacting a compound of formula (I): with a compound of formula (II): to form a compound of formula (III): wherein PG1 is tBu, PG2 is Fmoc and PG3 is Dde; and the reaction conditions involve the use of a base, wherein the base is 2,4,6-collidine or 2,6-dimethylpyridine; b) reacting the compound of formula (III) under conditions suitable for forming a compound of formula (IV): and c) reacting the compound of formula (IV) under conditions suitable for forming compound (V): 5. The method according to claim 4, wherein compound (II) is preactivated by reaction with 2-(1H-Benzotriazole-1-yl)-1,1,3,3-tetramethylaminium tetrafluoroborate (TBTU), 1-Hydroxy-7-azabenzotriazole (HOAt) and 2,4,6-collidine prior to reaction with compound (I). 6. The method of claim 5, wherein the preactivation takes place for 5 minutes or less. 7. The compound according to claim 1 of formula (VI) or a pharmaceutically acceptable salt thereof. 8. The compound according to claim 1 of formula (VII) or a pharmaceutically acceptable salt thereof. 9. A pharmaceutical or diagnostic composition comprising the compound according to claim 1. 10. The compound according to claim 1, wherein the compound is a cancer diagnostic or imaging agent. 11. A method of imaging and/or diagnosing cancer comprising administering an effective amount of the compound according to claim 1 to a patient in need thereof. 12. A method of treating cancer in a patient, comprising administering an effective amount of the compound according to claim 1 to a patient. 13. A method of diagnosing imaging or preventing neoangiogenesis/angiogenesis in a patient, comprising administering an effective amount of the compound according to claim 1 to a patient. 14. A method of diagnosing or imaging cancer or treating cancer wherein the cancer is prostate, breast, lung, colorectal or renal cell carcinoma in a patient, comprising administering an effective amount of the compound according to claim 1 to a patient.